Bristol-Myers Squibb Company (BMY) Shares Sold by Notis McConarty Edward

Notis McConarty Edward lowered its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 15,161 shares of the biopharmaceutical company’s stock after selling 250 shares during the period. Notis McConarty Edward’s holdings in Bristol-Myers Squibb were worth $824,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the last quarter. Jennison Associates LLC increased its position in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after purchasing an additional 178,436 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares during the last quarter. Legal & General Group Plc increased its position in shares of Bristol-Myers Squibb by 4.3% in the 1st quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after purchasing an additional 335,795 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after purchasing an additional 1,267,900 shares during the last quarter. 68.80% of the stock is owned by institutional investors.

In other news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/2886929/bristol-myers-squibb-company-bmy-shares-sold-by-notis-mcconarty-edward.html.

Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Credit Suisse Group reissued a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $66.00 target price on shares of Bristol-Myers Squibb in a research report on Monday. Finally, Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 target price for the company in a research report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $62.54.

Bristol-Myers Squibb Company (BMY) traded up 0.35% on Tuesday, reaching $62.94. 2,304,454 shares of the company’s stock traded hands. The stock has a market capitalization of $103.22 billion, a PE ratio of 22.99 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $63.47. The firm’s 50-day moving average is $57.59 and its 200 day moving average is $55.71.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the company posted $0.69 EPS. Analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.